MedTrace Logo

Nationwide Registry of Patients With Heart Failure With Improved and Supranormal Ejection Fraction

NCT07389564 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2026-02-05

No results posted yet for this study

Summary

NOVEL-HF is a multicenter, observational nationwide registry of HFimpEF and HFsnEF conducted in cooperation with the Scientific Platform of the Polish Society of Cardiology.

According to the current definitions the criteria for HFimpEF diagnosis include patients with HF with an initial left ventricular ejection fraction (LVEF) below 40%, with at least a 10% increase during follow-up, and with final values \>40%. HFsnEF includes patients with HF whose LVEF values on echocardiography are \>65%.

The patient data will be collected from standardized and anonymous forms via the Scientific Platform of the Polish Society of Cardiology. The NOVEL-HF registry will involve the complete clinical, laboratory, and echocardiographic characteristics, as well as introduced pharmacological treatment. The occurrence of end-points (all-cause mortality, cardiovascular mortality, HF decompensations, worsening of HF symptoms) will be assessed in short- and long-term follow-up.

In accordance with initial assumptions, 500 HFimpEF and 200 HFsnEF patients in all participating centers will be included.

Ethical approval was granted by the local Bioethics Committee.

Conditions

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-29
Primary Completion
2026-08-01
Completion
2026-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07389564 on ClinicalTrials.gov